Agomab Secures US Patent For AGMB-447, Investigational Inhaled Lung-Restricted Small Molecule Inhibitor Of ALK5 For Idiopathic Pulmonary Fibrosis Treatment

Agomab Therapeutics NV has been granted U.S. Patent No. 12,577,230 by the USPTO for AGMB-447, an investigational inhaled small molecule inhibitor of ALK5, which is currently undergoing a Phase 1b study for treating Idiopathic Pulmonary Fibrosis. The patent provides intellectual property protection for AGMB-447 in the U.S. until at least 2041, not accounting for any potential extensions.